Introduction
Since my last article on bluebird bio (BLUE) about 3 months ago, the company has faced several setbacks such as the delay in filing BLA of its lead program, Zynteglo for the treatment of transfusion-dependent ?-thalassemia ("TDT"), delay in the first commercial treatment for Zynteglo in Germany, and as a result of the impact of the COVID-19 pandemic on commercial, regulatory, and development timelines, the company announced that it would re-evaluate its operating plan and adjust its priorities and overall expenses. On a brighter note, the company recently shared that the submission of the